Quotes: MENA   Enter Symbol: NewsLetter: Search: advanced

Server is busy please try again later.  Join our daily free Newsletter

MENAFN Press - 17/10/2012
No. of Ratings : 0
Add to Mixx!



Due to technical reasons, this story has been removed from our database.

About CytoDyn Inc
CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. CytoDyn intends to explore the clinical development of Cytolin(R) for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. CytoDyn recently completed a humanized antibody construct of Cytolin(R), filed a provisional patent for its use, and manufacturing discussions are underway. In addition, CytoDyn is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin(R), CytoFeline(TM) and CytoDyn please go to www.cytodyn.com.Forward-Looking StatementsThis press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn's control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.

 


MENAFN Press




  MENA News Headlines
 Dec 21 2014 - US won't back Palestinian resolutionGulf Times
(MENAFN - Gulf Times) The US will not support the current resolution put forward by the Palestinians setting the terms of a peace deal with Israel, a US official said yesterday.Washington has seen ...

 Dec 21 2014 - Saudi retail firms profit up 11.2 percent in Q3MENAFN
(MENAFN) The Saudi's retail firms' net profit registered a growth by 11.2 percent to USD213.85 million during the July-September period of this year compared to USD192.41 million in the same period ...

 Dec 21 2014 - Italian Serie A results and standingsSaudi Press Agency
(MENAFN - Saudi Press Agency)  Results and standings Italian Serie A (kick-off times in GMT), according to dpa:Matchday 16:Thursday, December 18:Cagliari 1 Juventus 3Napoli 2 Parma 0Saturday, ...

 Dec 21 2014 - US blames North Korea for Sony cyber-attackGulf Times
(MENAFN - Gulf Times) The US government has blamed North Korea for a devastating cyber-attack against Sony Pictures, calling it an unacceptable act of intimidation and vowing to impose "costs and ...

 Dec 21 2014 - German Bundesliga results and standingsSaudi Press Agency
(MENAFN - Saudi Press Agency)   Results and standings in the German Bundesliga (kick-off times in GMT), according to dpa:Matchday 17:Friday, December 19:Mainz 1 Bayern Munich 2Saturday, December ...

 Dec 21 2014 - French Ligue 1 results and standingsSaudi Press Agency
(MENAFN - Saudi Press Agency)  Results and standings French Ligue 1 (kick-off times in GMT), according to dpa:Matchday 19:Friday, December 19:Lens 2 Nice 0Saturday, December 20:Paris Saint 0 ...

 Dec 21 2014 - English Premier League results and standingsSaudi Press Agency
(MENAFN - Saudi Press Agency)  Results and standings English Premier League (kick-off times in GMT), according to dpa:Matchday 17:Saturday, December 20:Manchester City 3 Crystal Palace 0Aston Villa 1 ...

 Dec 21 2014 - OIC condemns terrorist attack on Peshawar schoolSaudi Press Agency
(MENAFN - Saudi Press Agency)  Secretary General of the Organization of Islamic Cooperation (OIC) expressed today the organization's full support to the government and the people of Pakistan ...

 Dec 21 2014 - Royal Court Issues Statement 2 RiyadhSaudi Press Agency
(MENAFN - Saudi Press Agency)  Under leadership of Custodian of the Two Holy Mosques King Abdullah bin Abdulaziz Al Saud, the Kingdom of Saudi Arabia stressed its support and keenness on opening a ...

 Dec 21 2014 - Royal Court Issues StatementSaudi Press Agency
(MENAFN - Saudi Press Agency)  Based on keenness of Custodian of the Two Holy Mosques King Abdullah bin Abdulaziz Al Saud for unifying and removing obstacles between the Arab Republic of Egypt and ...

more...


 






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country

Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Economic Calendar
Financial Glossary


Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2014 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help